Enjoy complimentary customisation on priority with our Enterprise License!
The female sexual dysfunction treatment market size is forecast to increase by USD 21.69 billion at a CAGR of 51.9% between 2023 and 2028. Market growth hinges on diverse factors such as the rising incidence of chronic diseases, heightened awareness surrounding female sexual dysfunction, and the approval and accessibility of medications for treating hypoactive sexual desire disorder (HSDD). These elements collectively contribute to the expansion of the market, addressing critical healthcare needs and fostering advancements in sexual health solutions. The increasing prevalence of chronic conditions underscores the demand for effective treatments, while the growing recognition of dysfunction drives innovation and research in this domain. Moreover, the approval and availability of drugs targeting HSDD signify a significant milestone in addressing sexual wellness concerns, leading to improved healthcare outcomes and enhancing overall quality of life. It also includes an in-depth analysis of market trends and analysis, market growth analysis and challenges. Furthermore, the report includes historic market data from 2018 - 2022.
To learn more about this report, View Report Sample
The market is propelled by factors like the increasing awareness and acceptance of sexual health issues among menopausal women, addressing stress and anxiety related to sexual response, and advancements in treatments targeting female sexual arousal disorders. Trends include a focus on hormonal balance, specifically estrogen concentrations, and the emergence of innovative therapies like phosphodiesterase inhibitors. Challenges lie in overcoming societal taboos surrounding sexual health, addressing interpersonal difficulties affecting sexual satisfaction, and ensuring comprehensive and accessible treatment options for women facing FSD. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increased awareness of female sexual dysfunctions among women will drive the market's growth during the forecast period. The International Society for Sexual Medicine plays a leading role in ensuring that the latest evidence-based scientific developments in sexual medicine reach the entire target audience of both male and health practitioners and patients around the world. The organization focuses on investing in improved communications and marketing with the goal of providing more awareness, appreciation, and support for sexual medicine/health. Right to desire is a campaign for women with sexual dysfunctions. It is sponsored by Sprout Pharmaceuticals and aims to educate women regarding dysfunctions.
In addition, W2O Group, in collaboration with the American Sexual Health Association, launched an education program called Find My Spark. The program aims to encourage women to speak with their partners and health-care providers about any sexual difficulties they are facing. All such initiatives will contribute to the growth of the market during the forecast period.
Safety label changes for the dysfunction therapy will accelerate market growth during the forecast period. Addyi was approved in August 2015 for the treatment of hypoactive sexual desire disorder in women. However, US FDA reviewed data that included several concerning cases of severe low blood pressure and death when flibanserin and alcohol were taken together. Therefore, in April 2019, US FDA issued a safety labelling change order to Sprout Pharmaceuticals, which needs the company to revise the safety information for Addyi. The recent labelling of Addyi includes a box stating that alcohol must be avoided in women treated with flibanserin.
Furthermore, the US FDA has mandated a risk evaluation and mitigation strategy for Addyi, requiring certified healthcare professionals and pharmacies to implement specific measures under the risk evaluation and mitigation strategy program. This includes counseling patients about the risks associated with hypotension and syncope. Additionally, the FDA directed Sprout Pharmaceuticals to conduct further studies on the interaction between flibanserin (Addyi) and alcohol post-approval. These regulatory initiatives are aimed at enhancing patient safety and compliance, which are crucial factors in accelerating the market growth of urticaria drugs during the forecast period. As pharmaceutical companies and regulatory bodies collaborate to address safety concerns and optimize treatment outcomes, advancements in therapeutic options for urticaria and related conditions are expected to expand, meeting the evolving needs of patients and healthcare providers alike.
The adverse effects of drugs used in the treatment are the major challenge impeding the market growth. Sexual dysfunctions in women can be treated with hormonal therapy, which includes estrogen therapy and androgen therapy, as well as drugs, such as ospemifene (Osphena) and flibanserin (Addyi). However, these treatments are associated with adverse effects. The potential adverse effects of estrogen and androgen therapy include risks of breast and ovarian cancer, stroke, pulmonary thromboembolism, and vision loss caused by a blood clot in the eye. Osphena is an estrogen agonist which is prescribed for painful intercourse. The dose of Osphena is a 60 mg tablet, which needs to be taken once daily with food. The drug can cause cardiovascular disorders and malignant neoplasms.
According to clinical trials, incidence rates of thromboembolic and hemorrhagic stroke were 0.72 per 1,000 women and 1.45 per 1,000 women, respectively. Moreover, Osphena can cause allergic conditions, including hypersensitivity, angioedema, rash, rash erythematous, generalized rash, pruritus, and urticaria. Similarly, flibanserin can cause central nervous system depression with somnolence and sedation. It can also cause hypotension and syncope. Therefore, such adverse effects associated with the treatment of sexual dysfunctions in women can decrease patient compliance, thereby leading to a decline in the market's growth during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Pfizer - The company offers female sexual dysfunction treatment such as questionnaires and screeners. The company is engaged in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide.
The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market players, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth of the above 40 years segment will be significant during the forecast period. The above 40 years segment in the global market is expected to witness significant growth during the forecast period. This is due to the rising number of incidents of CVDs, diabetes, and cancer among the above 40 years age group. The prevalence of chronic diseases in the segment is expected to increase the patient pool and hence the segment growth.
Get a glance at the market contribution of various segments View the PDF Sample
The above 40 years segment was valued at USD 539.30 million in 2018 and continued to grow until 2022. The prevalence of cardiovascular diseases (CVDs) was high in many countries like India. Approximately 4.77 million were diagnosed as positive, with 20.2% diabetes, 53.7% hypertension, 77% overweight/obesity, and 92% central obesity in 2020. Similarly, in the UK, around 7600 women above 40 years were diagnosed with breast cancer in 2020. Such factors are anticipated to drive the demand for treatment in the above 40 years segment, which is expected to fuel the growth of the market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 61% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market in North America is led by the US. According to the data published by the CDC in 2020, nearly 9.5% of women in the US were diagnosed with diabetes during 2017-2018. The prevalence of breast cancer in the US was found to be 128.3 per 100,000 women. Therefore, the rising prevalence of chronic diseases will increase the risk and incidence of sexual dysfunction in women, which will drive market growth in the region during the forecast period. In addition, according to the data provided by the Blue Cross Blue Shield Association, a federation of 36 separate US health insurance companies, nearly 43% of American women were estimated to experience dysfunction to some degree every year across the US. An expected rise in the incidence of sexual dysfunction among women is expected to boost the demand for treatment, which in turn, is also expected to increase the growth opportunities in the market in North America during the forecast period.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
Sexual Enhancement Supplements Market Size: The Sexual Enhancement Supplements Market analysis North America, Europe, APAC, South America, Middle East and Africa - US, Canada, China, UK, Germany - Size and Forecast 2024-2028
Erectile Dysfunction (ED) Drugs Market Size: The Erectile Dysfunction (ED) Drugs Market analysis North America, Europe, APAC, South America, Middle East and Africa - US, Canada, China, UK, Germany - Size and Forecast 2024-2028
US - Premature Ejaculation (PE) Disorder Therapeutics Market Size: The US - Premature Ejaculation (PE) Disorder Therapeutics Market analysis North America - US - Size and Forecast 2024-2028
The Market is influenced by a range of factors encompassing cardiovascular disease, gynecological disorders, stress, and hormonal changes. Healthcare organizations are adopting telemedicine for effective consultation and treatment delivery. Treatment modalities include oral, parenteral, and topical medications available at hospital and drug pharmacies, retail outlets, and online stores. Conditions like dyspareunia and hypoactive sexual desire disorder (HSDD) are addressed with pharmacological options like bremelanotide and ospemifene. Additionally, non-estrogen therapies and psychotherapy play crucial roles. The market witnesses a growing demand for sexual health services, including counseling, testing, and education, supported by modern healthcare infrastructure, advanced technologies, and highly skilled professionals. Specialist clinics and research institutions contribute to evidence-based practices and holistic approaches to enhance female sexual health and overall well-being.
The Market addresses diverse concerns affecting women's sexual health, including menopausal transitions, chronic disorders like diabetes and malignant diseases, and gynecological conditions such as vulvovaginal atrophy and vaginismus. Treatment options range from pharmacological drugs like ospemifene to topical estrogen products, testosterone creams, and antidepressants. Genito-pelvic penetration pain disorders and hypoactive sexual desire disorders are specific segments targeted by therapies like pelvic floor exercises and hormone treatments. Medical professionals across disciplines, including gynecologists, physical therapists, sex therapists, and psychologists, provide comprehensive care in hospital and retail pharmacies and online platforms. Advanced medical technologies, coupled with research and education initiatives, contribute to holistic approaches addressing physiological and psychological factors impacting sexual satisfaction and functioning. Modern facilities, evidence-based practices, and societal awareness drive the evolution of the FSD treatment landscape towards personalized, effective, and stigma-free interventions.
Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 51.9% |
Market growth 2024-2028 |
USD 21.69 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
36.97 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 61% |
Key countries |
US, Canada, Germany, UK, and France |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Assos Ilac, Cipla Inc., DARE BIOSCIENCE INC., Dr Reddys Laboratories Ltd., Duchesnay Inc., Endo International Plc, Freya Pharma Solutions B.V., Lupin Ltd., Mithra Pharmaceuticals SA, Novo Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Pharmbio Korea Inc., Sprout Pharmaceuticals Inc., Strategic Science and Technologies LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Age Group
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.